Abivax SA American Depositary Shares - Asset Resilience Ratio
Abivax SA American Depositary Shares (ABVX) has an Asset Resilience Ratio of 2.58% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Abivax SA American Depositary Shares's Asset Resilience Ratio has changed over time. Check Abivax SA American Depositary Shares strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Abivax SA American Depositary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ABVX market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $14.13 Million | 2.58% |
| Total Liquid Assets | $14.13 Million | 2.58% |
Asset Resilience Insights
- Limited Liquidity: Abivax SA American Depositary Shares maintains only 2.58% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Abivax SA American Depositary Shares Industry Peers by Asset Resilience Ratio
Compare Abivax SA American Depositary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 2.34% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
Annual Asset Resilience Ratio for Abivax SA American Depositary Shares (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Abivax SA American Depositary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.34% | $13.69 Million | $584.09 Million | +2.28pp |
| 2024-12-31 | 0.07% | $136.00K | $205.23 Million | -2.70pp |
| 2023-12-31 | 2.77% | $9.05 Million | $327.06 Million | +2.76pp |
| 2022-12-31 | 0.01% | $6.00K | $75.54 Million | +0.00pp |
| 2021-12-31 | 0.01% | $6.00K | $109.23 Million | 0.00pp |
| 2020-12-31 | 0.01% | $6.00K | $71.30 Million | 0.00pp |
| 2019-12-31 | 0.01% | $6.00K | $51.73 Million | -9.25pp |
| 2018-12-31 | 9.26% | $5.01 Million | $54.05 Million | -18.89pp |
| 2017-12-31 | 28.15% | $15.15 Million | $53.81 Million | +3.32pp |
| 2016-12-31 | 24.84% | $15.05 Million | $60.60 Million | +6.48pp |
| 2015-12-31 | 18.36% | $14.00 Million | $76.27 Million | +13.87pp |
| 2014-12-31 | 4.49% | $1.70 Million | $37.97 Million | +3.45pp |
| 2013-12-31 | 1.04% | $400.00K | $38.46 Million | -- |
About Abivax SA American Depositary Shares
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials f… Read more